NCT02595203View on ClinicalTrials.gov

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Healthy
Interventions
DRUG

[14C-pos 1]-Debio 1450 BES Solution

A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1

DRUG

[14C-pos 25]-Debio 1450 BES Solution

A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit (CRU) Ltd., Leeds

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY